Regenxbio (NASDAQ:RGNX) had its target price trimmed by Morgan Stanley from $36.00 to $35.00 in a research report sent to investors on Wednesday morning. The firm currently has an overweight rating on the biotechnology company’s stock.
Other research analysts have also recently issued reports about the company. Zacks Investment Research upgraded Regenxbio from a hold rating to a buy rating and set a $33.00 price target for the company in a research note on Thursday, March 8th. BidaskClub upgraded Regenxbio from a hold rating to a buy rating in a research note on Saturday, February 10th. Raymond James Financial reiterated a buy rating on shares of Regenxbio in a research note on Friday, January 5th. Chardan Capital reiterated a buy rating on shares of Regenxbio in a research note on Monday, December 11th. Finally, TheStreet cut Regenxbio from a c rating to a d+ rating in a research note on Tuesday, November 28th. One investment analyst has rated the stock with a sell rating, three have assigned a hold rating and six have assigned a buy rating to the company. The company has a consensus rating of Buy and a consensus price target of $40.13.
Regenxbio (NASDAQ:RGNX) traded down $0.65 during midday trading on Wednesday, reaching $32.35. The company’s stock had a trading volume of 14,925 shares, compared to its average volume of 404,682. Regenxbio has a 12-month low of $16.30 and a 12-month high of $42.00.
Regenxbio (NASDAQ:RGNX) last announced its quarterly earnings results on Tuesday, March 6th. The biotechnology company reported ($0.51) EPS for the quarter, beating the Zacks’ consensus estimate of ($0.71) by $0.20. Regenxbio had a negative return on equity of 36.48% and a negative net margin of 704.02%. The company had revenue of $2.04 million during the quarter. equities analysts anticipate that Regenxbio will post -2.57 EPS for the current fiscal year.
In related news, insider Kenneth T. Mills sold 10,000 shares of the stock in a transaction on Wednesday, December 20th. The stock was sold at an average price of $31.75, for a total value of $317,500.00. Following the completion of the sale, the insider now directly owns 108,530 shares in the company, valued at $3,445,827.50. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Curran Simpson sold 30,000 shares of the stock in a transaction on Friday, December 22nd. The shares were sold at an average price of $33.03, for a total value of $990,900.00. Following the completion of the sale, the senior vice president now owns 69,500 shares of the company’s stock, valued at $2,295,585. The disclosure for this sale can be found here. Insiders sold 70,000 shares of company stock valued at $2,148,100 over the last 90 days. 17.00% of the stock is currently owned by company insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of RGNX. Wells Fargo & Company MN increased its holdings in Regenxbio by 1.1% in the second quarter. Wells Fargo & Company MN now owns 16,209 shares of the biotechnology company’s stock valued at $320,000 after purchasing an additional 175 shares during the period. Northern Trust Corp increased its holdings in Regenxbio by 40.8% in the second quarter. Northern Trust Corp now owns 304,184 shares of the biotechnology company’s stock valued at $6,008,000 after purchasing an additional 88,202 shares during the period. Vanguard Group Inc. increased its holdings in Regenxbio by 10.3% in the second quarter. Vanguard Group Inc. now owns 1,082,461 shares of the biotechnology company’s stock valued at $21,379,000 after purchasing an additional 100,944 shares during the period. Voya Investment Management LLC acquired a new stake in Regenxbio in the second quarter valued at $249,000. Finally, State Street Corp increased its holdings in Regenxbio by 178.1% in the second quarter. State Street Corp now owns 880,844 shares of the biotechnology company’s stock valued at $17,399,000 after purchasing an additional 564,129 shares during the period. Institutional investors and hedge funds own 69.22% of the company’s stock.
TRADEMARK VIOLATION NOTICE: “Regenxbio (RGNX) Price Target Cut to $35.00 by Analysts at Morgan Stanley” was first published by Dispatch Tribunal and is owned by of Dispatch Tribunal. If you are accessing this piece on another domain, it was illegally stolen and reposted in violation of United States & international trademark & copyright laws. The original version of this piece can be accessed at https://www.dispatchtribunal.com/2018/03/15/regenxbio-rgnx-price-target-cut-to-35-00-by-analysts-at-morgan-stanley.html.
Regenxbio Company Profile
REGENXBIO Inc is a clinical-stage biotechnology company. The Company’s gene therapy product candidates are designed to deliver genes to cells to address genetic defects or to enable cells in the body to produce therapeutic proteins or antibodies that are intended to impact disease. The Company develops products candidates across the therapeutic areas of metabolic, neurodegenerative and retinal diseases.
Receive News & Ratings for Regenxbio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Regenxbio and related companies with MarketBeat.com's FREE daily email newsletter.